Compound class

Growth hormone peptides

Growth hormone and related compounds.

Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.

Somatropin is recombinant human growth hormone,1 tesamorelin is a synthetic analogue of growth hormone-releasing factor,2 and ipamorelin is described as a growth hormone secretagogue.3 MK-677 (ibutamoren) is a non-peptide small molecule that FDA documents say is not a component of an FDA-approved drug,4 and a trial in older adults gave it by mouth once daily.5 FDA's 2026 briefing weighs against adding it to the 503A bulks list for compounding and describes a trial in older people recovering from hip fracture that was terminated early due to a safety signal of congestive heart failure.4 The WADA 2026 list names several of these compounds as prohibited at all times.6

Growth hormone peptides 20

Metabolic 1

Half-lives side by side

The figure each source gives, on one scale. Bars are ranges.

  • Sermorelin6 to 7 min, IV
  • Ipamorelin2 h, IV
  • Human growth hormone2.3 h
  • CJC-1295 with DAC8 to 10 days

Log scale, 1 minute to about 3 weeks. Each figure and its source are in the list above. Minutes, days and weeks are turned into hours (1 day is 24 hours) only to place them on the scale. These are the sources' figures; the half-life the app uses to draw levels can differ.

Where some figures in the list come from

  • Ipamorelin: FDA says a published study identified serious adverse events including death when ipamorelin was given intravenously for improving gastric motility.7

Guides 19

Calculators 15

Compare 4

Logged in Milligram

Share of people who logged a dose in Milligram in the 90 days to 15 November 2026 who logged each compound.

  • Tesamorelin11%
  • CJC-1295 + Ipamorelin4%
  • Human growth hormone4%
  • Ipamorelin4%

Tesamorelin, how often

  • Daily64%
  • Every other day27%
  • Twice a week5%
  • Weekly4%
  • Less often0%

CJC-1295 + Ipamorelin, how often

  • Daily67%
  • Every other day22%
  • Twice a week7%
  • Weekly3%
  • Less often0%

Human growth hormone, how often

  • Daily80%
  • Every other day14%
  • Twice a week2%
  • Weekly2%
  • Less often1%

Ipamorelin, how often

  • Daily63%
  • Every other day25%
  • Twice a week10%
  • Weekly1%
  • Less often1%

How often: among people with three or more logged doses, by the average gap between their doses.

Aggregated and anonymous, shares of people only. Each compound not listed: too few people logged it to show a share. It describes what people set up in the app, not advice on what to take.

References 14

  1. Pfizer Laboratories Div Pfizer Inc. GENOTROPIN (somatropin) for injection, prescribing information (DailyMed, effective 4 August 2026). 2026. DailyMed label
  2. Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection, prescribing information. 2026. DailyMed label
  3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. 1998. PMID 9849822
  4. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, October 29, 2024: Ibutamoren Mesylate. 2024. fda.gov
  5. Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996. PMID 8954023
  6. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. 2026. wada-ama.org
  7. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA category 2 list
  8. Ferring Pharmaceuticals Inc. Zomacton (somatropin) kit, prescribing information. DailyMed, label effective 20 April 2026. DailyMed label (Zomacton)
  9. Novo Nordisk. Norditropin (somatropin) injection, solution, prescribing information. DailyMed, label effective 7 July 2025. DailyMed label (Norditropin)
  10. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
  11. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. Springer, DOI 10.1007/s00384-014-2030-8
  12. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009;19:471-7. PMC2787983
  13. Irish Medicines Board. Summary of Product Characteristics: Geref 50 (sermorelin acetate), printed 13 July 2006. HPRA Geref 50 SmPC
  14. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register 2013;78(42):14095-14096. Federal Register 2013-04827

Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.